Article
Study Results Could Improve Quality of Life in Pediatric ALL
The study, conducted in 2 separate patient cohorts at St. Jude Children's Hospital and the Children's Oncology Group and published in the The Journal of the American Medical Association, found that children with gene variants in the CEP72 gene were more sensitive to vincristine-induced peripheral neuropathy.
Children with acute lymphoblastic leukemia who had a certain gene variant experienced a higher incidence and severity of peripheral neuropathy after receiving treatment with the cancer drug vincristine, according to a study in the February 24 issue of JAMA.
William E. Evans, PharmD, of St. Jude Children's Research Hospital, Memphis, and colleagues performed a genome-wide association study to determine whether there are genetic variants associated with vincristine-induced neuropathy. The study included patients in 1 of 2 prospective clinical trials for childhood ALL that included treatment with 36 to 39 doses of vincristine. Genetic analysis and vincristine-induced peripheral neuropathy were assessed in 321 patients from whom DNA was available: 222 patients (median age, 6.0 years) enrolled in 1994-1998 in a St. Jude Children's Research Hospital cohort; and 99 patients (median age, 11.4 years) enrolled in 2007-2010 in a Children's Oncology Group cohort.
Read the complete report on MedicalXpress: http://bit.ly/1EN9t0h
